Eurofins Financial Statements From 2010 to 2026
| ALECR Stock | EUR 16,100 1,700 9.55% |
Check Eurofins Cerep financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eurofins Cerep's main balance sheet or income statement drivers, such as , as well as many indicators such as . Eurofins financial statements analysis is a perfect complement when working with Eurofins Cerep Valuation or Volatility modules.
Eurofins |
Eurofins Cerep SA Company Current Valuation Analysis
Eurofins Cerep's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eurofins Cerep Current Valuation | 106.92 M |
Most of Eurofins Cerep's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eurofins Cerep SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Eurofins Cerep SA has a Current Valuation of 106.92 M. This is 99.26% lower than that of the Life Sciences Tools & Services sector and 99.94% lower than that of the Health Care industry. The current valuation for all France stocks is 99.36% higher than that of the company.
Eurofins Cerep SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eurofins Cerep's current stock value. Our valuation model uses many indicators to compare Eurofins Cerep value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eurofins Cerep competition to find correlations between indicators driving Eurofins Cerep's intrinsic value. More Info.Eurofins Cerep SA is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.49 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eurofins Cerep SA is roughly 2.03 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eurofins Cerep's earnings, one of the primary drivers of an investment's value.About Eurofins Cerep Financial Statements
Eurofins Cerep shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Eurofins Cerep investors may analyze each financial statement separately, they are all interrelated. The changes in Eurofins Cerep's assets and liabilities, for example, are also reflected in the revenues and expenses on on Eurofins Cerep's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France. Eurofins Cerep operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 149 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eurofins Stock Analysis
When running Eurofins Cerep's price analysis, check to measure Eurofins Cerep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eurofins Cerep is operating at the current time. Most of Eurofins Cerep's value examination focuses on studying past and present price action to predict the probability of Eurofins Cerep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eurofins Cerep's price. Additionally, you may evaluate how the addition of Eurofins Cerep to your portfolios can decrease your overall portfolio volatility.